Dec 8, 2008 - ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company announced that they have submitted an application to the U.S. Food and Drug Administration (FDA) to broaden the use of ERBITUX (cetuximab) to include first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) in combination with platinum-based chemotherapy (cisplatin/vinorelbine).
The details can be read here.
No comments:
Post a Comment